0727 GMT - The market is pricing in tariff risks for pharma stocks despite drugs currently being exempt from U.S. President Trump's potential tariffs, Berenberg analysts say in a note. Uncertainty from tariffs and substantial layoffs at the Food and Drug Administration and other U.S. health departments have dragged pharma share prices lower, they say. Berenberg reiterate its buy ratings on U.K. drugmaker AstraZeneca and French pharma giant Sanofi due to share-price erosion and lower exposure to the U.S. market. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 08, 2025 03:27 ET (07:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。